Plain-English translation of NCT06947460 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing CD19-BCMA CAR T cell therapy, a treatment that uses your own immune cells modified in a lab to fight three serious autoimmune diseases: lupus nephritis (kidney disease from lupus), systemic sclerosis (a disease causing skin and organ hardening), and Sjögren's syndrome with pulmonary hypertension (a syndrome causing dry eyes/mouth with high lung blood pressure). The therapy is designed to help patients whose conditions have not improved with standard treatments.
Some patients with these autoimmune diseases do not respond to conventional immunosuppressive medications and continue to get worse. This medication represents a newer approach that may help control the immune system in ways that standard drugs cannot.
You likely qualify if…
You likely don't qualify if…
You will come to Beijing GoBroad Hospital for screening visits to confirm you have the disease and meet all requirements. If you qualify, doctors will collect some of your blood to extract and modify your immune cells in a laboratory. After the cells are ready, you will receive an infusion of the modified cells. You will then be monitored closely over at least 28 days to watch for side effects and see how well the treatment works.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
China